Researchers at the Johns Hopkins Kimmel Cancer Center's Ludwig Center developed a new treatment that selectively targets ...

An antibody-drug conjugate (ADC) is a newly developed, highly-targeted type of cancer therapeutic. ADCs are created by grafting monoclonal antibodies to a cytotoxic payload. This new type of cancer ...

Researchers at the Johns Hopkins Kimmel Cancer Center's Ludwig Center developed a new treatment that selectively targets ...

Lifordi Immunotherapeutics and other biotechnology companies are using antibodies to precisely target drugs in the body.

Ipsen gains exclusive global rights, outside of Greater China, for development, manufacturing and commercialization of SIM0613, a ...

HDP-101, a novel antibody-drug conjugate, targets BCMA with a synthetic amanitin payload that causes tumor cell death. "I don't think I need to convince anyone here that we need to discover new ...

Combination therapy is a common cancer treatment strategy, the rationale being that two drugs together may be more effective than either one alone. Seagen and Nurix Therapeutics are embracing the ...

Raising $94 million in a series A round, South San Francisco-based Firefly Bio Inc. has emerged from stealth to advance its Firelink linker platform technology to develop degrader-antibody conjugates ...

The pharmaceutical industry’s antibody-drug conjugate( ADC) deal spree continues. AbbVie says it will buy ImmunoGen for about $10 billion, adding to a series of multi-billion dollar acquisitions built ...